RVTY
RevvityNYSEHealth CareDiagnostics & ResearchSnapshot 2026-05-08
As of May 8, 2026, RVTY has a composite score of 12.7 and a signal label of "mild favorable." The score is influenced by a medium confidence level of 76.8 and a moderate risk label. Key drivers include macroeconomic factors such as labor, rates, growth, and inflation. The analysis is provisional.
Price
Daily closes from AlphaVantage. Earnings/event dots are placed inline.
Factor signals
Read top-to-bottom: thesis (is this a strong company over a 1–3 year hold), watch flags (has something changed worth re-reading), and position context (how violent might the path be). Each pill is a parallel diagnostic — never aggregated into a single score.
Thesis
— is this a strong company over a 1–3 year hold?Why this rank
- Direction share1.00
- Slope (norm)0.12
- Bonus0.00
Why this rank
Trailing four: 2024-Q3, 2025-Q1, 2025-Q2, 2025-Q3
Why this rank
Joint read: strong + robust historically delivered 80%+ NI-grew rate over T+1y in IT 2024–26 (small N).
Watch
— has something changed worth re-reading?Why this setup
EPS estimate $1.29 → $1.22 (-5.6% / 30d). 0 raised, 5 cut, 13 covering analysts.
0 upgrades, 1 downgrade / 30d, 6 maintained. 44% of analysts rate Buy.
4 PT revisions / 30d. Avg target 20.5% above current price.
0 positive, 0 negative / 30d.
F4 · Management deep-dive — recent events, stated priorities, guidance track record
Recent 8-K events
2 material events in the last 24 months — top 2 listed below.
Stated priorities
2 priorityies extracted from earnings transcripts (as of 2026-05-08).
- 1.Organic revenue growth of 2-3% for 2026growthmixed65% progressprovisional
2/2: “The Company forecasts organic revenue growth of 2-3% for the full year 2026.”
Why this status
Stated in 2 of last 2 quarters. Revenue for 2025 was $2.86 billion, up from $2.76 billion in 2024, indicating a growth trajectory. The guidance for 2026 is consistent with past performance, suggesting steady progress.
- 3.Adjusted EPS guidance of $5.35-$5.45 for 2026growthmixed65% progressprovisional
2/2: “The Company forecasts adjusted EPS of $5.35-$5.45 for 2026.”
Why this status
Stated in 2 of last 2 quarters. Adjusted EPS for 2025 was $5.06, up from $4.90 in 2024, indicating a positive trend. The 2026 guidance suggests continued growth, aligning with past performance.
Guidance track record
Insufficient guidance history for this ticker.
Position context
— how violent might the path be while I hold it?Why this risk level
Recent vol — 30d annualized 49%; 252d 39%.
Drawdown — Max 1y −30%. Bad day move −4%.
Beta to sector ETF (XLV) — 1.40 over 1y.
Liquidity — score 100/100.
Sub-scores — vol 35/100, drawdown 40/100, beta 60/100, earnings vol —.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive — historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only — describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-05-08.
What changed
The most important moves since the prior daily snapshot.
- No material changes since the prior snapshot.
No material changes since the prior snapshot.
as of 2026-05-08
Management scorecard
How management runs the business — capital, margins, balance sheet, and how reliably they guide and deliver.
What management is focused on
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
- #1
Organic revenue growth of 2-3% for 2026
GrowthRevvity aims for organic revenue growth of 2-3% in 2026, reflecting steady market conditions.
MixedStated in 2 of last 2 quarters. Revenue for 2025 was $2.86 billion, up from $2.76 billion in 2024, indicating a growth trajectory. The guidance for 2026 is consistent with past performance, suggesting steady progress.
65%CEO/CFO:“The Company forecasts organic revenue growth of 2-3% for the full year 2026.”Press releaseSource dated 2026-02-02Stated 2 of last 8 quartersFirst seen 2026-02-02provisionalShow history (2)
- 2025-Q4Press release
“The Company forecasts organic revenue growth of 2-3% for 2026.”
- 2025-Q3Multiple sources
“Reaffirming its organic growth guidance of 2% to 4% for 2025.”
- #3
Adjusted EPS guidance of $5.35-$5.45 for 2026
GrowthRevvity projects adjusted earnings per share of $5.35-$5.45 for the full year 2026.
MixedStated in 2 of last 2 quarters. Adjusted EPS for 2025 was $5.06, up from $4.90 in 2024, indicating a positive trend. The 2026 guidance suggests continued growth, aligning with past performance.
65%CEO/CFO:“The Company forecasts adjusted EPS of $5.35-$5.45 for 2026.”Press releaseSource dated 2026-02-02Stated 2 of last 8 quartersFirst seen 2026-02-02provisionalShow history (2)
- 2025-Q4Press release
“Forecasts adjusted EPS of $5.35-$5.45 for 2026.”
- 2025-Q3Multiple sources
“Raised its adjusted EPS guidance to $4.90-$5.00 for 2025.”
How this stock is priced
Two ways to read price: against peers in the same business, and against the company's own history.
Roughly priced in line with peers.
Cheaper than its own typical valuation.
P/E over the last 5 years
71 monthly pointsHow this compares
A side-by-side read on composite, valuation, and risk versus peers.
| Stock | Composite | Valuation | Risk |
|---|---|---|---|
RVTY Revvity | +13 | fair | moderate |
LLY Lilly (Eli) | +21 | full | moderate |
JNJ Johnson & Johnson | +18 | full | low |
ABBV AbbVie | +12 | fair | low |
UNH UnitedHealth Group | +24 | fair | elevated |
Risk — how this stock moves
What a normal day looks like, what a bad day looks like, and the worst the last year has thrown at it.
What could change this view
Conditional scenarios — if X happens, the score would shift by about Y points. These are not predictions.
- If health_care sector trend rises from +0.06 into 'improving' (>= +0.20)+5.0 pts
- If next-quarter guidance is raised (currently NEW as of 2026-05-05)+4.0 pts
- If next-quarter guidance is cut (currently NEW as of 2026-05-05)-8.0 pts
- If labor state reverses from -0.31 (negative) to +0.31 (positive)-6.8 pts
- If health_care sector trend falls from +0.06 into 'weakening' (<= -0.20)-5.0 pts
Material updates
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
- 2026-05-053d agoItem 2.02
of Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
earnings preannouncementneutralscore 61 - 2026-05-053d agoItem 8.01
Other Events Exhibit 99.2 to the Current Report on Form 8-K sets forth the unaudited pro forma condensed consolidated financial statements to present the pro forma financial position and results of operations of Revvity, Inc. and Subsidiaries (the “Company”) based upon historical financial information after giving effect to the probable sale of all of the assets related to the Company’s Immunodiagnostics business in China (“China IDX”) pursuant to a letter of intent signed on April 16, 2026.…
mna activityneutralscore 48 - 2026-02-023mo agoItem 2.02
Results of Operations and Financial Condition On February 2, 2026 , Revvity, Inc. announced its financial results for the fourth quarter and fiscal year ended December 28, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or…
earnings preannouncementneutralscore 7 - 2025-10-246mo agoItem 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On October 23, 2025, the Board of Directors (the “Board”) of Revvity, Inc. (the “Company”) appointed Anita Gonzales, the Company’s Vice President and Controller, to serve as its Vice President and Chief Accounting Officer, effective immediately. Mrs. Gonzales, 49, has served as the Company’s Vice President and Controller since May 2023, having joine…
executive changeneutralscore 1
Score history
The composite score, snapshot by snapshot. The dotted line at zero separates leaning-positive from leaning-negative.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.